[The efficacy of active specific immunotherapy using modified neoplastic cells in the combined modality treatment of hemoblastoses].
Efficiency was studied of active specific immunotherapy (IT) with cell vaccine consisting of allogenic viable cryopreserved modified Con A blast cells identical with the illness in patients with acute myeloblastic leukemia and acute lymphoblastic leukemia. The studies made confirmed a positive impact of IT on the clinical course of acute leukosis (prolonged remission, keeping down infectious complications), on leukopoiesis, peripheral blood cells enzymatic status as well as on cell immunity, certain factors of humoral immunity and bodily natural antineoplastic resistance.
Zverkova
A S
AS
Bratus'
G G
GG
Darchuk
G F
GF
Komissarenko
V G
VG
Koval'
A I
AI
Tretiak
N N
NN
Gashchuk
A P
AP
Vakul'chuk
A M
AM
Ruzhinskaia
E E
EE
Dzhevadova
I V
IV
D000917:Antibody Formation / Q000187:drug effects / Q000276:immunology; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D019496:Cancer Vaccines / Q000627:therapeutic use*; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects / Q000276:immunology; D007114:Immunization; D016233:Immunotherapy, Active / Q000379:methods*; D015470:Leukemia, Myeloid, Acute / Q000276:immunology / Q000628:therapy*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000276:immunology / Q000628:therapy*; D012074:Remission Induction; D013997:Time Factors
D019496:Cancer Vaccines